newsfilter
← Latest News
GlobeNewswire·

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

  • Jade Biosciences, Inc. (NASDAQ: JBIO) appointed Mark Eisner, M.D., M.P.H. to its Board of Directors effective June 25, 2026.
  • Dr. Eisner brings over 25 years of leadership in clinical development and immunology, having most recently served as Executive Vice President and Chief Medical Officer at Vir Biotechnology.
  • His previous experience includes roles as Chief Medical Officer at Sonoma Biotherapeutics and FibroGen, and nearly 11 years at Genentech/Roche where he led global development programs for immunology, infectious disease, and ophthalmology.
  • CEO Tom Frohlich stated Dr. Eisner's experience in guiding therapies from early development through regulatory approval will support Jade's pipeline of antibody-based treatments for autoimmune diseases.
  • Jade's lead candidate JADE101 targets the cytokine APRIL for immunoglobulin A nephropathy, while its pipeline also includes JADE201, an anti-BAFF-R monoclonal antibody, and JADE301, an undisclosed program.
  • The company was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
  • The press release includes standard forward-looking statements regarding future expectations, risks, and uncertainties associated with clinical trials and regulatory approvals.